

Tremfya IV (guselkumab)

Fax completed form to: (855) 840-1678 If this is an URGENT request, please call (800) 882-4462 (800.88.CIGNA)

PHYSICIAN INFORMATION * Physician Name: Specialty: * DEA, NPI or TIN:			PATIENT INFORMATION *Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this			
Office Contact Person:			* Patient Name:			
Office Phone:		* Cigna ID:	* Date	* Date of Birth:		
Office Fax:			* Patient Street Address:			
Office Street Address:			City:	State:	Zip:	
City:	State:	Zip:	Patient Phone:			
Urgency:			ing this box, I attest to the fact that opardize the customer's life, healt			
Medication requested: Tremfya IV ICD10: Directions for use:		Dose and Quantity	: Dura	ation of thera	ару:	
Where will this medicati Accredo Specialty Pharm Hospital Outpatient Prescriber's office stock (Other (please specify): **Medication orders can be p NCPDP 4436920), Fax 888.	acy** billing on a mec placed with Acc	lical claim form) redo via E-prescribe		ealth / Home ationally pres	e Infusion vendor ferred specialty pharmacy emphis, TN 38134-8822	
Facility and/or doctor di	spensing and	d administering m	nedication:			
Facility Name: Address (City, State, Zip Co	de):	State:	Тах	ID#:		
Is the requested medication the patient?	for a chronic or	long-term condition	for which the prescription medi	ication may	be necessary for the life of ☐ Yes ☐ No	
molecule drug? Biologic (an adalimumab Entyvio (IV or SC), Ilumya, ir rituximab IV product [Rituxar biosimilar], Taltz, a tocilizum Targeted synthetic oral si Xeljanz, Xeljanz XR, Velsipit Conventional synthetic D	agnoses n be administer product [Humira nfliximab IV prod n, biosimilar], Sł ab product [Acto mall molecule d y, or Zeposia.) MARD (such as	a, biosimilar], Bimzel ducts [Remicade, bic kyrizi (IV or SC), Silic emra (IV or SC), bios rug (such as Cibinqo s methotrexate, leflur	ith a BIOLOGIC or in combinat x, Cosentyx (IV or SC), etaner psimilar], Kevzara, Kineret, Om g, Simponi [Aria or SC]), an ust similar], Tremfya (IV or SC), or o, Leqselvi, Litfulo, Sotyktu, Olu nomide, hydroxychloroquine, or on with another BIOLOGIC or t	cept SC pro voh (IV or S cekinumab p Zymfentra umiant, Otez r sulfasalaziu	oduct [Enbrel, biosimilar], SC), Orencia [IV or SC], a product [Stelara (IV or SC), zla, Rinvoq, Rinvoq LQ, ne)	

(if UC) Has the patient had a trial of one systemic therapy for ulcerative colitis? Please Note: Examples include 6-me azathioprine, cyclosporine, tacrolimus, or a corticosteroid such as prednisone, methylprednisolone. A trial of a mesa does not count as a systemic therapy for ulcerative colitis.				
(if no) Has the patient had a trial of a biologic for ulcerative colitis? Please Note: Examples include an adalir (Humira, biosimilars), Entyvio (IV or SC), an infliximab IV product (Remicade, biosimilars), Omvoh, Zymfent Skyrizi, or an ustekinumab product [Stelara (IV or SC)]. A biosimilar of the requested biologic does not coun	ra, Simponi SC, it			
(if no) Does the patient have pouchitis?	☐ Yes ☐ No ☐ Yes ☐ No			
(if no biologic for UC) Has the patient tried an antibiotic, probiotic, corticosteroid enema, or mesala Please Note: Examples of antibiotics include metronidazole and ciprofloxacin. Examples of corticos include hydrocortisone enema.				
(if CD) Has the patient tried a systemic corticosteroid or is currently taking a systemic corticosteroid?	🗌 Yes 🗌 No			
(if no) Is a systemic corticosteroid contraindicated in this patient?	🗌 Yes 🗌 No			
(if no) Has the patient tried one other conventional systemic therapy for Crohn's disease? Please N systemic therapies for Crohn's disease include azathioprine, 6-mercaptopurine, and methotrexate. mesalamine does not count as a systemic agent for Crohn's disease.				
(if no) Has the patient had a previous trial of one biologic for Crohn's disease other than th drug? Please Note: A biosimilar of the requested biologic does not count. Examples of bio Cimzia, Entyvio, an infliximab IV product (Remicade, biosimilars), an adalimumab product biosimilars), Omvoh (IV or SC), Skyrizi (IV or SC), an ustekinumab product [Stelara (IV or Zymfentra.	ologics include t (Humira,			
(if no) Does the patient have enterocutaneous (perianal or abdominal) or rectova	iginal fistulas? □ Yes □ No			
(if no) Has the patient had an ileocolonic resection (to reduce the chanc disease recurrence)?				
Will the requested medication be used as induction therapy?	🗌 Yes 🗌 No			
Is this medication being prescribed by or in consultation with a gastroenterologist?	🗌 Yes 🗌 No			
Additional Pertinent Information: Please provide any additional pertinent clinical information, including: if the p on the requested drug (with dates of use) and how they have been receiving it (for example: samples, out of pocket).				
Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that th insurer its designees may perform a routine audit and request the medical information necessary to verify the accurate information reported on this form.				
Prescriber Signature: Date:				
Save Time! Submit Online at: <u>www.covermymeds.com/main/prior-authorization-forms/cigna/</u> or via SureScr	ipts in your EHR.			
Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it your call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cign				
"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cig its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Suc subsidiaries include for example. Cigna Health and Life Insurance Company and Cigna Health Management. Inc., Address: Cigna Pharmacy S	ch operating			

subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005